source
- Sciwind has two Western partners for its obesity drug, but is open to moreSciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet. The Chinese biotech is seeking new partners for the righ…Endpoints · 1mo ago↗ source
- The seeming inevitability of rising healthcare costsWe’re getting our first signs of where healthcare costs are heading next year. According to a survey of actuaries at 27 health plans covering employers and individuals on the exchangesEndpoints · 1mo ago↗ source
- Summit pulls $500M share sale a day after announcing itThe developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.